50 / 1851
Pharmacological Research 117 (2017) 406–415
Targeting EGFR T790M mutation in NSCLC:
From biology to evaluation and treatment
Osimertinib (AstraZeneca ) is a potent, irreversible EGFR tyrosine kinase inhibitor
that is selective for EGFR tyrosine kinase inhibitor–sensitizing mutations and the
T790M resistance mutation with an excellent therapeutic index because its activity
is poor towards the wild-type EGFR
Olmutinib (HM 61713)(Boehringer Ingelheim) is an irreversible tyrosine-kinase
inhibitor, selective for mutant EGFR. Its molecule structure contains a Michael
acceptor that covalently binds a cysteine residue near the kinase domain of mutant
EGFR